MX9801165A - Metodo y composicion para el tratamiento del asma. - Google Patents

Metodo y composicion para el tratamiento del asma.

Info

Publication number
MX9801165A
MX9801165A MX9801165A MX9801165A MX9801165A MX 9801165 A MX9801165 A MX 9801165A MX 9801165 A MX9801165 A MX 9801165A MX 9801165 A MX9801165 A MX 9801165A MX 9801165 A MX9801165 A MX 9801165A
Authority
MX
Mexico
Prior art keywords
patient
antigen
molecular weight
composition
asthma
Prior art date
Application number
MX9801165A
Other languages
English (en)
Other versions
MXPA98001165A (es
Inventor
Tahir Ahmed
Samuel Broder
John K Whisnant
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of MX9801165A publication Critical patent/MX9801165A/es
Publication of MXPA98001165A publication Critical patent/MXPA98001165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para tratar a un paciente que sufre de asma inducida por un antígeno, quien se ha excitado con este antígeno, o suministrar un tratamiento cronico a un paciente de asma para reducir la hiper-sensibilidad de las vías respiratorias, este método comprende la administracion intra-bronquial al paciente de una composicion farmacéutica que contiene en cada dosis aproximadamente 0.05 a 1.0 mg de heparinas de peso molecular ultra-bajo (ULMWH), que tienen un peso molecular promedio pondreal de 3,000 daltons o menos, por kilogramo del peso corporeo del paciente. Las composiciones farmacéuticas para la inhalacion, usadas en el novedoso método de tratamiento, también son provistas.
MXPA/A/1998/001165A 1995-08-18 1998-02-11 Metodo y composicion para el tratamiento del asma MXPA98001165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08516786 1995-08-18
US08/516,786 US5690910A (en) 1995-08-18 1995-08-18 Method for treating asthma

Publications (2)

Publication Number Publication Date
MX9801165A true MX9801165A (es) 1998-07-31
MXPA98001165A MXPA98001165A (es) 1998-11-09

Family

ID=

Also Published As

Publication number Publication date
HUP9901614A2 (hu) 1999-09-28
AR003271A1 (es) 1998-07-08
PL324970A1 (en) 1998-06-22
AU6694596A (en) 1997-03-12
SK17298A3 (en) 1998-09-09
JPH11511196A (ja) 1999-09-28
DE69635023T2 (de) 2006-05-24
SK282759B6 (sk) 2002-12-03
DE69635023D1 (de) 2005-09-08
WO1997006783A1 (en) 1997-02-27
CA2229060A1 (en) 1997-02-27
EP0844869A4 (en) 2003-04-09
UA62919C2 (en) 2004-01-15
DK0844869T3 (da) 2005-12-12
ATE300938T1 (de) 2005-08-15
CZ48198A3 (cs) 1998-11-11
NZ337996A (en) 2001-04-27
AU701691B2 (en) 1999-02-04
PT844869E (pt) 2005-10-31
EP0844869A1 (en) 1998-06-03
JP3263723B2 (ja) 2002-03-11
KR19990037688A (ko) 1999-05-25
PL186912B1 (pl) 2004-03-31
EP0844869B1 (en) 2005-08-03
US5690910A (en) 1997-11-25
ZA966838B (en) 1997-02-19
CZ292134B6 (cs) 2003-08-13
IL123166A0 (en) 1998-09-24
IL123166A (en) 2002-07-25
HUP9901614A3 (en) 2000-04-28
KR100451901B1 (ko) 2005-09-12
ES2244974T3 (es) 2005-12-16
HK1007060A1 (en) 1999-04-01
NZ315275A (en) 2000-01-28

Similar Documents

Publication Publication Date Title
NZ315275A (en) Inhalant composition including ultra low mw heparins (ULMWH) to treat asthma
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
CA2298445A1 (en) Method and compositions for treating late phase allergic reactions and inflammatory diseases
GB9316895D0 (en) Hepatoselective insulin analogues
GB9519661D0 (en) Fatty acid treatment
EP0682526A4 (en) LENGTH ADMINISTRATION OF SCR1 AND OTHER COMPLEMENT INHIBITORS.
HUT75156A (en) New pharmaceutical composition containing combination of formoterol and budesonide
AU4934496A (en) Method for in vitro preconditioning of myoblasts before transplantation
HUT71224A (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
GR3035231T3 (en) Use of sulodexide and of medicines containing it for the treatment of diabetic nephropathy.
AU573262B2 (en) Covalently bound heparin-antithrombin iii complex
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
AU571641B2 (en) Dietry dextran formulations
WO1999059628A3 (en) Combination therapy for the treatment of tumors
CA2216789A1 (en) Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
JPS6419020A (en) Estrodiene oral drug for administrative to oral cheek portion and administration therefor
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
US5385731A (en) Method of treating hyperlipidemia with granulocyte colony stimulating factor
UA6738A (uk) Спосіб лікування бронхообструктивного синдрому у хворих на бронхіальну астму та хронічний обструктивний бронхіт
UA30912A (uk) Спосіб терапії хворих на хронічний обструктивний бронхіт
UA10069A (uk) Спосіб профілактики та лікування гнойної раневої інфекції
MD197G2 (ro) Preparat şi procedeu de tratare a hipogalactiei